Alison D Treister1, Cheryl Kraff-Cooper2, Peter A Lio3. 1. Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 2. Kraff Eye Institute, Chicago, Illinois. 3. Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Abstract
Importance: Clinical trials of dupilumab for atopic dermatitis (AD) have reported an increased incidence of conjunctivitis in patients who received dupilumab compared with those who received placebo. Objective: To describe the characteristics of patients who develop conjunctivitis secondary to dupilumab treatment for AD. Design, Setting, and Participants: Case series of 12 patients who reported development of conjunctivitis from a cohort of 142 patients treated with dupilumab for AD at a secondary care center from March 14, 2017, to March 29, 2018. Exposures: Patients received a 600-mg injection of dupilumab as a loading dose and a 300-mg injection every 2 weeks thereafter. Main Outcomes and Measures: Primary outcome measures were severity of AD as measured by the Investigator Global Assessment (IGA) score, a 5-point scale from 0 (clear) to 4 (severe), at the time of dupilumab initiation and at conjunctivitis onset. Results: Of the 12 patients included in this series, 7 (58%) were male. The mean (SD) age of patients was 30 (8.1) years at the time conjunctivitis developed. All patients showed improvement of their AD at the time of conjunctivitis diagnosis, with a mean (SD) 1.9 (0.8)-point decrease in IGA score and 47.8% (11.2%) decrease in body surface area affected. Nine of the 12 patients (75%) had severe baseline AD with an IGA score of 4. All patients who discontinued treatment had severe AD at the time of initial dupilumab administration and had at least 1 atopic condition in addition to AD. Conclusions and Relevance: Conjunctivitis that develops after administration of dupilumab to treat AD may be severe enough to necessitate stopping therapy. Severe conjunctivitis was more likely to develop in patients with more severe baseline AD who had a good response to dupilumab and an increased atopic phenotype. Studies are needed to confirm risk factors associated with development of conjunctivitis and to determine effective treatment.
Importance: Clinical trials of dupilumab for atopic dermatitis (AD) have reported an increased incidence of conjunctivitis in patients who received dupilumab compared with those who received placebo. Objective: To describe the characteristics of patients who develop conjunctivitis secondary to dupilumab treatment for AD. Design, Setting, and Participants: Case series of 12 patients who reported development of conjunctivitis from a cohort of 142 patients treated with dupilumab for AD at a secondary care center from March 14, 2017, to March 29, 2018. Exposures: Patients received a 600-mg injection of dupilumab as a loading dose and a 300-mg injection every 2 weeks thereafter. Main Outcomes and Measures: Primary outcome measures were severity of AD as measured by the Investigator Global Assessment (IGA) score, a 5-point scale from 0 (clear) to 4 (severe), at the time of dupilumab initiation and at conjunctivitis onset. Results: Of the 12 patients included in this series, 7 (58%) were male. The mean (SD) age of patients was 30 (8.1) years at the time conjunctivitis developed. All patients showed improvement of their AD at the time of conjunctivitis diagnosis, with a mean (SD) 1.9 (0.8)-point decrease in IGA score and 47.8% (11.2%) decrease in body surface area affected. Nine of the 12 patients (75%) had severe baseline AD with an IGA score of 4. All patients who discontinued treatment had severe AD at the time of initial dupilumab administration and had at least 1 atopic condition in addition to AD. Conclusions and Relevance: Conjunctivitis that develops after administration of dupilumab to treat AD may be severe enough to necessitate stopping therapy. Severe conjunctivitis was more likely to develop in patients with more severe baseline AD who had a good response to dupilumab and an increased atopic phenotype. Studies are needed to confirm risk factors associated with development of conjunctivitis and to determine effective treatment.
Authors: Jacob P Thyssen; Peter B Toft; Anne-Sofie Halling-Overgaard; Gunnar H Gislason; Lone Skov; Alexander Egeberg Journal: J Am Acad Dermatol Date: 2017-08 Impact factor: 11.527
Authors: Andrew Blauvelt; Marjolein de Bruin-Weller; Melinda Gooderham; Jennifer C Cather; Jamie Weisman; David Pariser; Eric L Simpson; Kim A Papp; H Chih-Ho Hong; Diana Rubel; Peter Foley; Errol Prens; Christopher E M Griffiths; Takafumi Etoh; Pedro Herranz Pinto; Ramon M Pujol; Jacek C Szepietowski; Karel Ettler; Lajos Kemény; Xiaoping Zhu; Bolanle Akinlade; Thomas Hultsch; Vera Mastey; Abhijit Gadkari; Laurent Eckert; Nikhil Amin; Neil M H Graham; Gianluca Pirozzi; Neil Stahl; George D Yancopoulos; Brad Shumel Journal: Lancet Date: 2017-05-04 Impact factor: 79.321
Authors: Johanna Tukler Henriksson; Terry G Coursey; David B Corry; Cintia S De Paiva; Stephen C Pflugfelder Journal: Invest Ophthalmol Vis Sci Date: 2015-07 Impact factor: 4.799
Authors: Eric L Simpson; Carsten Flohr; Lawrence F Eichenfield; Thomas Bieber; Howard Sofen; Alain Taïeb; Ryan Owen; Wendy Putnam; Marcela Castro; Kendra DeBusk; Chin-Yu Lin; Athina Voulgari; Karl Yen; Theodore A Omachi Journal: J Am Acad Dermatol Date: 2018-01-17 Impact factor: 11.527
Authors: Eric L Simpson; Thomas Bieber; Emma Guttman-Yassky; Lisa A Beck; Andrew Blauvelt; Michael J Cork; Jonathan I Silverberg; Mette Deleuran; Yoko Kataoka; Jean-Philippe Lacour; Külli Kingo; Margitta Worm; Yves Poulin; Andreas Wollenberg; Yuhwen Soo; Neil M H Graham; Gianluca Pirozzi; Bolanle Akinlade; Heribert Staudinger; Vera Mastey; Laurent Eckert; Abhijit Gadkari; Neil Stahl; George D Yancopoulos; Marius Ardeleanu Journal: N Engl J Med Date: 2016-09-30 Impact factor: 91.245
Authors: Quinn Thibodeaux; Mary Patricia Smith; Karen Ly; Kristen Beck; Wilson Liao; Tina Bhutani Journal: Hum Vaccin Immunother Date: 2019-03-27 Impact factor: 3.452
Authors: Maria C Schneeweiss; Richard Wyss; Kristyn Chin; Joseph F Merola; Jonathan I Silverberg; Arash Mostaghimi; Sebastian Schneeweiss Journal: Dermatitis Date: 2022-02-15 Impact factor: 4.867
Authors: Sunny Park; Jung Hyun Lee; Ji Hyun Park; So Hyang Park; Song Yi Park; Yong Woo Jung; Soo An Choi Journal: Sci Rep Date: 2021-07-12 Impact factor: 4.379